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OBJECTIVE — In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts
cardiovascularevents,andthepreventionofLVHiscardioprotective.Wesoughttocomparethe
effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evi-
dence of LVH (ECG-LVH).
RESEARCH DESIGN AND METHODS — This prespeciﬁed study compared the inci-
dence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2
diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who
had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE
inhibition with trandolapril (2 mg/day) or to non-ACE inhibitor therapy. Treatment was titrated
tosystolic/diastolicbloodpressure130/80mmHg.ECGreadingswerecentralizedandblinded
to treatment.
RESULTS — Baseline characteristics of the two groups were similar. Over a median (inter-
quartile range) follow-up of 36 (24–48) months, 13 of the 423 patients (3.1%) receiving
trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy
developedECG-LVH(hazardratio[HR]0.34[95%CI0.18–0.65],P0.0012unadjusted,and
0.35 [0.18–0.68], P  0.0018 adjusted for predeﬁned baseline covariates). The HR was signif-
icant even after adjustment for follow-up blood pressure and blood pressure reduction versus
baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages signiﬁcantly de-
creased with trandolapril but did not change with non-ACE inhibitor therapy.
CONCLUSIONS — ACE inhibition has a speciﬁc protective effect against the development
of ECG-LVH that is additional to its blood pressure–lowering effect. Because ECG-LVH is a
strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition
may be cardioprotective in this population.
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L
eft ventricular hypertrophy (LVH), a
cardinal manifestation of preclinical
cardiovascular disease, strongly pre-
dicts myocardial infarction, stroke, and
cardiovascular death in patients with hy-
pertension (1) or coronary artery disease
(2), as well as in the general population
(3).IntheFraminghamStudy,electrocar-
diographic(ECG)evidenceofLVH(ECG-
LVH) was associated with a twofold
increase in mortality over that resulting
from hypertension alone (4).
Studies have consistently shown that
antihypertensive therapy may effectively
limit the incidence of ECG-LVH, regard-
less of the treatments used to reduce
blood pressure (5). However, the Heart
Outcomes Prevention Education (HOPE)
(6)andtheLosartanInterventionforEnd-
point Reduction in Hypertension (LIFE)
trials (7) showed that, in patients with
ECG-LVH at inclusion, the ACE inhibitor
ramipril and the angiotensin receptor
blocker (ARB) losartan, respectively, re-
gressed LVH more effectively than drugs
thatdonotdirectlyinterferewiththerenin-
angiotensin-aldosterone system (RAAS).
The ﬁnding in both trials that this beneﬁt
was signiﬁcant even after adjustments for
the small differences in blood pressure
between the two treatment groups pro-
vided consistent evidence that RAAS in-
hibitor therapy has a speciﬁc
cardioprotective effect that exceeds ex-
pectations based on changes in blood
pressure alone. However, the HOPE trial
(6) was not powered to assess the treat-
menteffectonnew-onsetLVHinthesub-
group with no ECG-LVH at baseline, and
the LIFE trial (7) included only patients
with LVH. Thus, whether RAAS inhibitor
therapy may also prevent new-onset
LVH in subjects with normal left ven-
tricular mass to start with is unknown.
To formally explore this issue, we com-
pared the effect of ACE versus non-ACE
inhibitor therapy on incident ECG-LVH
in patients from the Bergamo Nephro-
logic Diabetes Complications Trial
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LVH at inclusion.
RESEARCH DESIGN AND
METHODS— BENEDICT (8) was a
prospective, randomized, double-blind,
parallel group study that evaluated the
possibility of preventing the onset of per-
sistent microalbuminuria in 1,204 pa-
tients with type 2 diabetes (World Health
Organization criteria) and arterial hyper-
tension (systolic or diastolic blood pres-
sure 130 or 85 mmHg or concomitant
antihypertensivetherapy)butnormaluri-
naryalbuminexcretionrate(20g/min
in at least two of three consecutive over-
night urine collections) who were ran-
domly assigned to at least 3 years of
treatment with one of the following study
drugs: 1) a nondihydropyridine calcium
channel blocker (240 mg/day verapamil
SR), 2) an ACE inhibitor (2 mg/day tran-
dolapril), 3) a ﬁxed-dose combination
(180 mg/day verapamil SR plus 2 mg/day
trandolapril [VeraTran]), and 4) placebo.
The target blood pressure after random
assignment and throughout the whole
study period was 130/80 mmHg for all
ofthetreatmentgroups.Otherantihyper-
tensivedrugs(withtheexceptionofRAAS
inhibitors and nondihydropyridine cal-
cium channel blockers different from the
studydrugs)couldbeusedtoachieveand
maintain the target blood pressure ac-
cording to predeﬁned guidelines (8). The
studyprotocolwasinaccordancewiththe
DeclarationofHelsinkiandwasapproved
by the institutional review board at each
center and by the safety committee of
BENEDICT. All patients gave written in-
formed consent. Patients were eligible to
enter the ECG-LVH substudy if they had
no ECG evidence of LVH at baseline and
had at least 1 year of follow-up.
Aims
The primary aim of analyses was to com-
pare the incidence of ECG-LVH in pa-
tientsrandomlyassignedtoACEinhibitor
ornon-ACEinhibitortherapywhohadno
ECG evidence of LVH at baseline. Sec-
ondarily, we evaluated the relationships
between incidence of ECG-LVH and
baseline and follow-up variables, includ-
ing treatable risk factors such as blood
pressure and A1C.
ECG-LVH and other outcome
variables
The main outcome variable was ECG-
LVH deﬁned as Sokolow-Lyon (SV1 
RV5/6) voltage 3.5 mV (12) and/or Cor-
nell (RaVL  SV3) voltage 2.0 mV
(women) or 2.4 mV (men) (13). Sec-
ondary outcomes were Sokolow-Lyon
and Cornell voltages considered as con-
tinuousvariables.Standard12-leadECGs
were recorded at 25 mm/s and 1 mV/cm
calibration at baseline and every year
thereafter. They were centrally and inde-
pendently evaluated by two investigators
who were blinded to treatment allocation
and patient data. ECGs with inconsistent
readings were evaluated by a third inde-
pendent cardiologist, and his diagnosis
was considered for data analysis. Trough
systolic and diastolic (Korotkoff phase
I/V) blood pressure was measured in the
morning before treatment administration
(8).
Data were reported in dedicated case
report forms and doubly entered in an ad
hoc database that was eventually merged
with the BENEDICT database. Before
analyses, all data were monitored by the
Monitoring Unit of the Clinical Research
Center for Rare Diseases “Aldo & Cele
Dacco `” of the Mario Negri Institute for
Pharmacological Research.
Sample size
We assumed a 10% incidence of ECG-
LVH in the non-ACE inhibitor group and
a 60% reduction (from 10 to 4%) in the
ACE inhibitor group. The expected inci-
dence of ECG-LVH was assumed to be
higherthanthatintheHOPEcontrolsub-
jects (6) because, different from the
HOPE trial, all BENEDICT patients were
hypertensiveanddiabeticatinclusion(8),
and they also had additional risk factors
such as older age, systolic hypertension,
obesity, and, conceivably, insulin resis-
tance. The 60% risk reduction was as-
sumed on the basis of experimental
evidence that ACE inhibition fully pre-
vents LVH if treatment is started before
the induction of arterial hypertension
(14). Because our patients were already
hypertensive at study entry and had other
risk factors, we considered a conservative
assumption of 60% risk reduction as ap-
propriate. Thus, we calculated that 400
patients per group gave the study a 90%
power to detect as statistically signiﬁcant
(0.05, two-tailed test) the expected
between-group difference in incidence of
ECG-LVH.
Statistical analyses
The analyses were performed by the Lab-
oratory of Biostatistics of the Clinical
Research Center. Between-group com-
parisonswereperformedoncontinuous
variables by unpaired t test or Wilcox-
on’s rank-sum test and on categorical
variables by a 
2 test or Fisher’s exact
test. Within-group comparisons were
performed on continuous variables by
paired t test or Wilcoxon’s signed-rank
test and on categorical variables by the
McNemar test. Predeﬁned (8) baseline
covariates were considered: site, age,
sex, smoking status (patients who had
never smoked versus former smokers
and current smokers), diastolic blood
pressure, and log-transformed urinary
albumin excretion (median of three
readings) at baseline.
The main study results were reported
by a Cox regression model. For graphic
representation,Kaplan-Meiercurveswere
plotted for each group considered. Ex-
ploratory analyses were also conducted,
including follow-up systolic and diastolic
blood pressure measurement and abso-
lute reductions from baseline for follow
up of blood pressure measurement to
help data interpretation. All statistical
analyses were performed using SAS (ver-
sion 9.1; SAS Institute, Cary, NC). P 
0.05 was considered statistically signiﬁ-
cant. No P value adjustment was carried
out for multiple comparisons.
RESULTS— Of 905 patients with
readable ECG at baseline and at least 1
year of follow-up, 816 (433 receiving
ACE and 383 receiving non-ACE inhibi-
tor therapy) had no ECG evidence of
LVH. Of these, 799 patients (423 receiv-
ing ACE and 376 receiving non-ACE in-
hibitor therapy) were available for
analyses (see study proﬁle in Online Ap-
pendix 2 [available at http://dx.doi.org/
10.2337/dc08-0371]). Baseline
characteristics and Sokolow-Lyon and
Cornell voltages were similar between
treatment groups with the exception of
the percentage of never smokers and of
serum cholesterol levels that were higher
inthenon-ACEinhibitorgroup(Table1).
Incidence of ECG-LVH
Over a median (interquartile range) of 36
(24–48) months of follow-up, LVH de-
veloped in 44 patients (5.5%), 13 (3.1%)
receiving ACE and 31 (8.2%) receiving
non-ACE inhibitor therapy (Fig. 1). The
unadjusted hazard ratio (HR) [95% CI]
forECG-LVHwas0.34[0.18–0.65](P
0.0012). The HR (0.35 [0.18–0.68]) was
statistically signiﬁcant even after adjust-
ment for predeﬁned baseline characteris-
tics (P  0.0018) and baseline and
follow-up systolic and diastolic blood
ACE inhibitors prevent LVH in diabetes
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blood pressure reduction versus baseline
(Table 2).
Compared with baseline, both
Sokolow-Lyon and Cornell voltages sig-
niﬁcantly decreased at different years on
follow-up in the study group as a whole
andinthesubgroupreceivingACEinhib-
itor therapy (Table 3). In the non-ACE
inhibitor group, changes in Sokolow-
Lyon voltage were not signiﬁcant, and
changes in Cornell voltage achieved sta-
tistical signiﬁcance only at 2 and 3 years
(Table 3).
Blood pressure and metabolic
control
Follow-up systolic (138.4  9.4 mmHg)
and diastolic (80.8  5.2 mmHg) blood
pressure was 12.7 and 7.1 mmHg lower
thanatbaseline,respectively(P0.0001
for both). Follow-up systolic (137.2 
9.2 vs. 139.7  9.5 mmHg, respectively,
P  0.045) and diastolic (80.0  5.2 vs.
81.7  5.0 mmHg, P  0.005) blood
pressurewaslowerintheACEthaninthe
non-ACE inhibitor group. Follow-up
A1C levels were lower in the ACE than in
the non-ACE inhibitor group (5.76 
1.17 vs 5.91  1.23%, P  0.03),
whereas blood glucose was similar in the
two treatment groups (156.1  36.2 vs.
161.339.1mg/dl,P0.31)(seeblood
pressure,A1C,andbloodglucoseproﬁles
in Online Appendix 3 [available at http://
dx.doi.org/10.2337/dc08-0371]).
In multivariable analyses, known di-
abetes duration, baseline BMI, and
Sokolow-Lyon and Cornell voltages were
associated with the incidence of ECG-
LVH on follow-up, whereas baseline and
follow-up systolic and diastolic blood
pressure, A1C, and blood glucose as well
as systolic and diastolic blood pressure,
A1C, and blood glucose changes versus
baseline had no predictive value. No sig-
niﬁcant correlation was found between
changesinSokolow-LyonorCornellvolt-
ages on follow-up and concomitant
changes in blood pressure, A1C, and
blood glucose (versus baseline).
Comparative analyses between
randomization arms
LVH developed in 4 patients receiving
trandolapril (1.9%), 9 receiving VeraTran
(4.2%), 16 receiving verapamil (8.9%),
and 15 receiving placebo (7.6%). After
adjustment for predeﬁned covariates, the
risk of LVH was signiﬁcantly lower with
trandolapril than with verapamil (HR
0.22 [95% CI 0.07–0.65)], P  0.007) or
Figure 1— Kaplan-Meier curves for the percentages of subjects receiving ACE inhibitor therapy
with trandolapril (ACEi YES) or receiving non-ACE inhibitor therapy (ACEi NO) who developed
ECG-LVH. The difference in ECG-LVH adjusted for prespeciﬁed baseline covariates was signiﬁ-
cant (P  0.0018).
Table 1—Baseline characteristics of hypertensive patients with type 2 diabetes and normal
urinary albumin excretion in the study group as a whole and according to ACE inhibitor
therapy (yes or no)
Overall ACE inhibitor yes ACE inhibitor no
n 799 423 376
Age (years) 61.6  8.0 61.5  7.8 61.7  8.2
Male sex 443 (55.4) 238 (56.3) 205 (54.5)
BMI (kg/m
2) 29.1  4.8 29.2  5.1 29.1  4.6
Known duration of
diabetes (years)
7.5  6.5 7.5  6.6 7.6  6.3
Smokers
Never 435 (54.4) 213 (50.4) 222 (59.0)*
Former 257 (32.2) 147 (34.7) 110 (29.3)
Current 107 (13.4) 63 (14.9) 44 (11.7)
A1C (%)† 5.8  1.4 5.7  1.4 5.7  1.3
Glucose (mg/dl) 160.4  45.7 159.1  45.6 161.9  45.9
Trough blood pressure
(mmHg)
Systolic 150.4  14.0 150.0  14.0 150.9  14.0
Diastolic 87.6  7.5 87.5  8.0 87.8  7.0
Mean arterial pressure 108.6  8.3 108.3  8.5 108.9  8.0
Urinary albumin excretion
(g/min)
5.2 (3.6–8.9) 5.2 (3.6–9.3) 5.2 (3.6–8.8)
Serum creatinine (mol/l) 79.6  17.7 79.6  17.7 79.6  17.7
Triglycerides (mmol/l) 1.65  0.91 1.63  0.83 1.66  1.00
Cholesterol (mmol/l) 5.41  0.93 5.33  0.93 5.50  0.93*
Sokolow-Lyon voltage (mV) 19.2  5.8 19.2  5.9 19.2  5.7
Cornell voltage (mV) 13.4  4.2 13.2  4.2 13.6  4.2
DataaremeansSD,n(%),ormedian(interquartilerange).*P0.05versusACEinhibitoryes.†A1Cwas
measured by ion-exchange high-performance liquid chromatography (normal range 3.5–5.2%).
Ruggenenti and Associates
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and with VeraTran compared with vera-
pamil (0.42 [0.19–0.97], P  0.0.043).
Risk reduction with VeraTran compared
with placebo was not signiﬁcant (0.49
[0.21–1.16], P  0.10). Risk was not sig-
niﬁcantlydifferentbetweenVeraTranand
trandolapril (1.97 ([0.60–6.49], P 
0.26)andbetweenverapamilandplacebo
(1.21 [0.58–2.52], P  0.61).
CONCLUSIONS — In the present
study, ACE inhibition with trandolapril
signiﬁcantly reduced the incidence of
ECG-LVH in patients with arterial hyper-
tension and type 2 diabetes compared
with non-ACE inhibitor therapy. The
protective effect of trandolapril against
ECG-LVH was already evident at 1 year
after random assignment and progres-
sively increased on follow-up. Sokolow-
Lyon and Cornell voltages consistently
decreased with trandolapril therapy,
whereas they did not change appreciably
with non-ACE inhibitor therapy.
The reduced incidence of ECG-LVH
with trandolapril was not explained by
the small differences in blood pressure
control between the two treatment
groups,becauseriskreductionwashighly
signiﬁcant even after adjustments were
made for blood pressure control achieved
on follow-up and for blood pressure re-
ductions observed versus baseline. Base-
line factors potentially involved in LVH
development and progression, such as
age, BMI, blood pressure, and Sokolow-
Lyon and Cornell voltages were similar in
the two groups. A low-salt diet was pre-
scribed for all patients, and no patient
performed vigorous physical activities.
Altogether, the above data indicate that
trandolapril had a speciﬁc protective ef-
fect against the development of LVH that
was additional to the beneﬁt of blood
pressure reduction.
Bothhemodynamicandnonhemody-
namic factors most likely contributed to
the cardioprotective effect of trandolapril
therapy. ACE inhibitors increase vessel
wall compliance and reduce arterial wave
reﬂection amplitude and thus reduce aor-
tic and left ventricular blood pressure
even more consistently than peripheral
artery blood pressure, that is, the brachial
blood pressure as measured at the arm
(15). Thus, at comparable peripheral
blood pressure, ACE inhibitors may re-
ducecentralpressuresandleftventricular
afterload more effectively than antihyper-
tensivedrugsthatdonotdirectlyinterfere
with the RAAS (16). These hemodynamic
effectsprobablycontributedtotheregres-
sion of LVH observed with RAAS inhibi-
tor therapy in the HOPE (6) and LIFE
trials (7) and might also explain why in
BENEDICT trandolapril prevented LVH
more effectively than non-ACE inhibitor
therapy, even at comparable brachial
blood pressure (9).
ACEinhibitorsmaypreventLVHalso
through direct inhibition of cardiac
RAAS. Angiotensin II promotes the
growth of myocytes independently of
loading conditions (17), and ACE inhibi-
tors may prevent the hypertrophic effect
of angiotensin II even at doses that do not
affect the blood pressure (14). Renin ex-
pression and tissue-converting enzyme
activity are increased in hypertrophied
hearts of spontaneously hypertensive rats
(18,19), and angiotensin II type 1 (AT1)
receptors are overexpressed in cardiomy-
ocytes of mice with cardiac hypertrophy
and normal blood pressure (20). Consis-
tently, in rats, cardiac expression of the
AT1 receptor antisense transgene attenu-
ated cardiac hypertrophy without affect-
ing the blood pressure (21). However,
recent data that cardiac AT1 receptors
cannot sustain angiotensin II-dependent
hypertensionandcardiachypertrophyaf-
terknocking-outrenalAT1receptors(22)
suggest that kidney RAAS activation is
also involved and that its inhibition may
explain at least part of the cardioprotec-
tive effect of ACE inhibitors and ARBs.
UnlikeARBs,ACEinhibitorsmaydirectly
prevent myocardial hypertrophy also by
increasing local bradykinin bioavailabil-
ity through inhibition of the myocardial
kallikrein-kinin pathway (23).
Vascular stiffness and RAAS activa-
tion (24) are common in patients with
type 2 diabetes, and this may explain the
high prevalence and severity of LVH in
Table 2—HR (95% CI) of the incidence of ECG-LVH in patients randomly assigned to ACE
inhibitor therapy compared with patients randomly assigned to non-ACE inhibitor therapy
HR (95% CI) P value
Unadjusted 0.34 (0.18–0.65) 0.0012
Adjusted
Baseline predeﬁned 0.35 (0.18–0.68) 0.0018
Baseline SBP 0.36 (0.18–0.68) 0.0019
Baseline DBP 0.36 (0.19–0.69) 0.0020
Follow-up SBP 0.38 (0.20–0.73) 0.0036
Follow-up DBP 0.34 (0.18–0.67) 0.0016
SBP reduction 0.35 (0.18–0.68) 0.0018
DBP reduction 0.34 (0.18–0.66) 0.0013
DBP, diastolic blood pressure; SBP, systolic blood pressure.
Table 3—Changes in Sokolow-Lyon and Cornell voltages at different years versus baseline in the study group as a whole (overall) and
according to ACE or non-ACE inhibitor therapy
1 year 2 years 3 years 4 years
Solokow-Lyon (mV)
Overall 	0.5  0.1* 	1.1  0.2† 	1.2  0.2† 	1.3  0.3
ACE inhibitor 	0.6  0.2* 	1.4  0.2‡ 	1.4  0.2† 	1.7  0.4
non-ACE inhibitor 	0.3  0.2 	0.7  0.2 	1.0  0.3 	0.8  0.4
Cornell (mV)
Overall 	0.4  0.1* 	0.5  0.2‡ 	0.4  0.1‡ 	0.3  0.2‡
ACE inhibitor 	0.5  0.1† 	0.8  0.1‡ 	0.6  0.2‡ 	0.4  0.3‡
non-ACE inhibitor 	0.2  0.2 	0.2  0.3† 	0.3  0.2* 	0.2  0.4
Data are means  SEM. *P  0.001, †P  0.01, ‡P  0.0001 versus baseline.
ACE inhibitors prevent LVH in diabetes
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pressure (8,9). The synergistic effect on
leftventricularstructureofarterialhyper-
tension and of the above hemodynamic
and metabolic abnormalities most likely
explained the relatively high incidence of
ECG-LVH we observed in our present
control subjects receiving non-ACE in-
hibitor therapy. On the other hand, all
of the above risk factors for LVH can be
controlled by ACE inhibitor therapy.
Indeed, in addition to inhibiting angio-
tensin II and aldosterone production,
ACE inhibitors may also ameliorate ar-
terial compliance (25). Thus, the coex-
istence of several abnormalities that can
be ameliorated by RAAS inhibitors may
also explain the remarkable protective
effect of trandolapril against ECG-LVH
we observed here, an effect that appears
to exceed that of ramipril in the HOPE
trial (6).
Post hoc analyses according to the
four original randomization arms showed
that trandolapril alone prevented LVH
more effectively than verapamil alone or
placebo, whereas trandolapril combined
with verapamil was more cardioprotec-
tive than verapamil alone. Trandolapril
alone tended to be more effective than
trandolapril combined with verapamil,
whereas the effect of verapamil was simi-
lar to that of placebo. Within the limita-
tions of the limited power and multiple
comparisons, these data show, consistent
with the results of primary outcome anal-
yses,thattheACEinhibitoristheeffective
component of the trandolapril-verapamil
combination and that verapamil has no
speciﬁc protective effect against LVH.
A possible limitation of the present
study is that, as in previous large studies
(4,6,7), LVH was assessed by electrocar-
diography. This probably resulted in re-
duced precision of outcome data (ECG
may underestimate LVH in obese sub-
jects) that reduced the power of the anal-
yses but probably was not likely to
introduce a systematic bias. Actually, a
posterior power analyses showed that the
probability of a false-positive ﬁnding was
0.2%.
In summary, hypertensive patients
with type 2 diabetes receiving trandola-
pril had a signiﬁcantly lower incidence
of ECG-LVH by Sokolow-Lyon and
Cornellvoltagethancontrolsubjectsre-
ceiving non-ACE inhibitor therapy, an
effect that was highly signiﬁcant even
after adjustments for blood pressure
control achieved in the two treatment
groups throughout the study. These
ﬁndings and the observation that ECG-
LVH strongly predicts cardiovascular
morbidity and mortality in people with
hypertension and type 2 diabetes sup-
port the use of early ACE inhibitor ther-
apy for effective prevention of left
ventricular hypertrophy and, conceiv-
ably, cardiovascular morbidity and
mortality (6,7) in this population.
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